This inventor holds 1 USPTO granted patent. Top assignee: Beckman Research Institute, City of Hope. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Innovations of Anna Gevorgyan in Cancer Research
Introduction
Anna Gevorgyan is an accomplished inventor based in San Pedro, California, recognized for her contributions to cancer research. She holds a significant patent that addresses critical aspects of cancer treatment and management, showcasing her dedication to improving outcomes for patients battling this disease.
Latest Patents
Anna's notable patent, titled "Identification and characterization of cancer stem cells and methods of use," focuses on a subpopulation of cancer stem cells that express elevated levels of uPAR among cancer cells. This groundbreaking work provides methods for treating proliferative disorders such as cancer by administering uPAR inhibitors. Additionally, her patent outlines ways to predict the likelihood of cancer recurrence, prevent such recurrences, and assess a cancer's responsiveness to specific therapies.
Career Highlights
Anna Gevorgyan is currently affiliated with City of Hope, a renowned research institution specializing in cancer treatment and research. Her journey in the field of cancer innovation highlights her commitment to advancing medical knowledge and therapeutic approaches.
Collaborations
Throughout her career, Anna has collaborated with esteemed colleagues, including Margarita Gutova and Chu-Chih Shih. These partnerships exemplify the collaborative spirit prevalent in the field of cancer research, contributing to the ongoing battle against this formidable illness.
Conclusion
Anna Gevorgyan's contributions to the field of cancer research through her patent and collaborations signify her role as an influential inventor. Her work not only furthers scientific understanding but also paves the way for innovative treatment options that could significantly impact patient lives.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
